Is Max Healthcare overvalued or undervalued?

As of October 29, 2021, Max Healthcare Institute Ltd. is considered very expensive with a PE ratio of 100.29, significantly higher than its peers, indicating it may be overvalued despite a 43% return over the past year compared to the Sensex's 7.55%.

As of 29 October 2021, the valuation grade for Max Healthcare Institute Ltd. moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE Ratio of 100.29, a Price to Book Value of 12.11, and an EV to EBITDA of 62.71. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Max Healthcare's valuation appears steep, as it has a higher PE ratio than many competitors in the healthcare sector. For instance, while Max Healthcare's PE stands at 100.29, other industry players typically exhibit lower ratios, indicating that investors may be paying a high price for expected growth that may not materialize. Notably, the company's stock has outperformed the Sensex over the past year, with a return of 43% compared to the Sensex's 7.55%, which may have contributed to the inflated valuation.

Who are in the management team of Max Healthcare?

As of March 2023, the management team of Max Healthcare includes Chairman Abhay Soi, along with several non-executive and independent directors: Anil Bhatnagar, K Narasimha Murthy, Mahendra Lodha, Michael Thomas Neeb, Pranav Amin, Amrita Gangotra, and Narayan Seshadri.

As of March 2023, the management team of Max Healthcare includes the following individuals:<BR><BR>1. Abhay Soi - Chairman / Executive Director<BR>2. Anil Bhatnagar - Non-Executive & Non-Independent Director<BR>3. K Narasimha Murthy - Independent Non-Executive Director<BR>4. Mahendra Lodha - Independent Non-Executive Director<BR>5. Michael Thomas Neeb - Independent Non-Executive Director<BR>6. Pranav Amin - Independent Non-Executive Director<BR>7. Amrita Gangotra - Independent Non-Executive Director<BR>8. Narayan Seshadri - Non-Executive Director<BR><BR>These individuals play various roles within the company's governance structure.

Has Max Healthcare declared dividend?

Max Healthcare Institute Ltd has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of August 23, 2024. The company has shown significant price appreciation over the years, particularly with a total return of 220.75% over three years.

Max Healthcare Institute Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 23 Aug 24<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 6.09%, with a dividend return of 0%, resulting in a total return of 6.09%.<BR><BR>For the 1-year period, the price return was 40.24%, the dividend return was 0.19%, leading to a total return of 40.43%.<BR><BR>Over the 2-year period, the price return was 122.44%, with a dividend return of 0.42%, culminating in a total return of 122.86%.<BR><BR>In the 3-year period, the price return reached 220.06%, while the dividend return was 0.69%, resulting in a total return of 220.75%.<BR><BR>For the 4-year period, the price return was 373.32%, with a dividend return of 0.98%, leading to a total return of 374.3%.<BR><BR>In the 5-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, Max Healthcare has declared a dividend, which contributes to its total returns, particularly noticeable over longer periods. The company shows strong price appreciation, especially in the 3 to 4-year periods, despite lower dividend contributions.

Who are the peers of the Max Healthcare?

Max Healthcare's peers include Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institute, Rainbow Child, Dr. Agarwal's Health, and Jupiter Life Line. Among these, Max Healthcare and Apollo Hospitals show excellent growth and management risk, while Krishna Institute has the highest 1-year return at 85.24%.

Peers: Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Aster DM Health., Krishna Institu., Rainbow Child., Dr Agarwal's Hea, Jupiter Life Lin.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Krishna Institu., Rainbow Child., Dr Agarwal's Hea, and Jupiter Life Lin, while Average management risk is found at Fortis Health. and Aster DM Health. Growth is excellent at Max Healthcare and Apollo Hospitals, good at Fortis Health., Narayana Hrudaya, Dr Agarwal's Hea, and Jupiter Life Lin, while below average growth is noted at Aster DM Health., Krishna Institu., and Rainbow Child. Capital structure is excellent at Max Healthcare, Global Health, Krishna Institu., and Jupiter Life Lin, average at Apollo Hospitals, and good at Fortis Health., Narayana Hrudaya, Dr Agarwal's Hea, and Rainbow Child., while below average is seen at Aster DM Health.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krishna Institu. at 85.24%, while the lowest is Dr Agarwal's Hea with no available data. Max Healthcare's 1-year return of 50.36% is significantly higher than Apollo Hospitals' 16.20% but lower than Krishna Institu.'s. Additionally, Aster DM Health. and Dr Agarwal's Hea have negative six-month returns.

What does Max Healthcare do?

Max Healthcare Institute Ltd is a large-cap hospital company in India, reporting net sales of ₹19,097 Cr and a net profit of ₹3,190 Cr for March 2025. It has a market capitalization of ₹123,419 Cr and key financial metrics include a P/E ratio of 109.00 and a return on equity of 12.08%.

Overview:<BR>Max Healthcare Institute Ltd operates in the hospital industry and is categorized as a large-cap company.<BR><BR>History:<BR>The company was originally incorporated as "Infinitum Technologies Private Limited" in New Delhi, India, on June 18, 2001. It changed its name to "Max Healthcare Institute Private Limited" following a Fresh Certificate of Incorporation dated June 28, 2002. The latest quarterly results reported are for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 19,097 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 3,190 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 123,419 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 109.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.24% <BR>Debt Equity: 0.25 <BR>Return on Equity: 12.08% <BR>Price to Book: 13.03 <BR><BR>Contact Details:<BR>Address: Not available <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Max Healthcare?

The top shareholders of Max Healthcare include Abhay Soi with 23.73%, Foreign Institutional Investors holding 54.74%, and mutual funds with 13.38%. The Government of Singapore is the largest public shareholder at 5.69%, while individual investors own 3.31%, with no pledged promoter holdings.

The top shareholders of Max Healthcare include a mix of institutional and individual investors. The largest shareholder is Abhay Soi, who holds 23.73% of the company. Foreign Institutional Investors (FIIs) are significant shareholders as well, collectively holding 54.74% of the shares, represented by 1020 FIIs. Additionally, mutual funds have a presence with 13.38% held across 33 schemes. The Government of Singapore is the highest public shareholder, owning 5.69%. Individual investors collectively hold 3.31% of the shares. Notably, there are no pledged promoter holdings.

How big is Max Healthcare?

As of 24th July, Max Healthcare Institute Ltd has a market capitalization of 122,491.00 Cr, with recent Net Sales of 7028.46 Cr and a Net Profit of 1075.88 Cr. Shareholder's Funds are 9,380.87 Cr, and Total Assets are valued at 15,186.44 Cr.

As of 24th July, Max Healthcare Institute Ltd has a market capitalization of 122,491.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 7028.46 Cr and a Net Profit of 1075.88 Cr.<BR><BR>As of March 2025, the Shareholder's Funds amounted to 9,380.87 Cr, while the Total Assets were valued at 15,186.44 Cr.

When is the next results date for Max Healthcare?

The next results date for Max Healthcare is 13 August 2025.

The next results date for Max Healthcare is scheduled for 13 August 2025.

Are Max Healthcare latest results good or bad?

Max Healthcare's latest results show strong sales growth and a significant increase in operating profit, but a decline in net profit and cash flow, along with rising debt, indicate underlying challenges that need to be addressed. Overall, the performance is mixed, reflecting both positive trends and concerns.

Max Healthcare's latest results present a mixed picture. On one hand, the company achieved its highest quarterly net sales in the last five quarters, reaching Rs 2,027.57 crore, which indicates a positive trend in sales growth. Additionally, operating profit increased to Rs 522.91 crore, and the profit after tax for the last six months grew by an impressive 28.53%, reflecting strong year-on-year performance.<BR><BR>However, there are notable challenges as well. The company's consolidated net profit saw a decline of 3.46% compared to the previous quarter, which is concerning. Furthermore, operating cash flow has decreased to Rs 598.01 crore, the lowest in three years, suggesting issues with cash revenues from operations. The debt-equity ratio has also risen to 0.32 times, indicating increased borrowing, while cash and cash equivalents have fallen, which could affect short-term liquidity.<BR><BR>In summary, while there are positive aspects such as growth in sales and profitability, the decline in net profit and cash flow, along with increased debt, suggest that the overall performance is somewhat flat and presents challenges that the company needs to address.

How has been the historical performance of Max Healthcare?

Max Healthcare has experienced substantial growth from Mar'20 to Mar'25, with net sales increasing from 1,059.03 Cr to 7,028.46 Cr, and profit after tax rising from 12.91 Cr to 1,075.88 Cr. Total assets grew from 3,973.66 Cr to 15,186.44 Cr, reflecting the company's successful expansion strategy.

Answer:<BR>Max Healthcare has shown significant growth in its historical performance, particularly in net sales, which increased from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. This upward trend is reflected in total operating income, which also rose from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. The total expenditure, excluding depreciation, grew from 965.45 Cr in Mar'20 to 5,179.66 Cr in Mar'25, indicating increased operational costs alongside revenue growth. Operating profit (PBDIT) has similarly improved, climbing from 141.66 Cr in Mar'20 to 2,004.44 Cr in Mar'25, while profit before tax increased from 12.78 Cr in Mar'20 to 1,406.37 Cr in Mar'25. The profit after tax also saw a rise, reaching 1,075.88 Cr in Mar'25 compared to 12.91 Cr in Mar'20. The company's earnings per share (EPS) increased from 1.1 in Mar'20 to 11.07 in Mar'25, showcasing enhanced profitability per share. On the balance sheet, total assets grew from 3,973.66 Cr in Mar'20 to 15,186.44 Cr in Mar'25, while total liabilities increased from 3,973.66 Cr to 2,488.83 Cr in the same period. Cash flow from operating activities improved significantly, reaching 1,459.00 Cr in Mar'25, although cash flow from investing activities showed a negative trend at -1,614.00 Cr.<BR><BR>Breakdown:<BR>Max Healthcare's financial performance has demonstrated remarkable growth over the years, particularly in net sales, which surged from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. This growth in revenue is accompanied by a corresponding increase in total operating income, which reached 7,028.46 Cr in Mar'25, up from 1,059.03 Cr in Mar'20. The company's total expenditure also rose significantly, from 965.45 Cr in Mar'20 to 5,179.66 Cr in Mar'25, reflecting the costs associated with scaling operations. Operating profit (PBDIT) has shown a strong upward trajectory, increasing from 141.66 Cr in Mar'20 to 2,004.44 Cr in Mar'25, while profit before tax improved from 12.78 Cr to 1,406.37 Cr in the same period. The profit after tax reached 1,075.88 Cr in Mar'25, a substantial increase from 12.91 Cr in Mar'20. The earnings per share (EPS) also rose significantly, indicating improved profitability for shareholders. On the balance sheet, total assets expanded from 3,973.66 Cr to 15,186.44 Cr, while total liabilities increased from 3,973.66 Cr to 2,488.83 Cr, reflecting the company's growth strategy. Additionally, cash flow from operating activities improved to 1,459.00 Cr in Mar'25, despite a negative cash flow from investing activities of -1,614.00 Cr, indicating ongoing investments in growth.

Is Max Healthcare technically bullish or bearish?

As of December 2, 2025, Max Healthcare's technical stance is mildly bearish, driven by bearish MACD and moving averages, despite some mildly bullish signals from Bollinger Bands and Dow Theory.

As of 2 December 2025, the technical trend has changed from bearish to mildly bearish. The current technical stance for Max Healthcare is mildly bearish. Key indicators driving this stance include a bearish MACD on the weekly chart and a bearish moving average on the daily chart. The Bollinger Bands show a mildly bullish signal on the monthly timeframe, but the overall sentiment remains cautious due to the bearish signals from the KST and MACD on the weekly timeframe. The Dow Theory indicates a mildly bullish trend on the weekly, but the lack of strong bullish signals across other indicators suggests a prevailing bearish sentiment.

Which are the latest news on Max Healthcare?

Why is Max Healthcare falling/rising?

As of 03-Dec, Max Healthcare Institute Ltd's stock price is currently 1,086.20, reflecting a decline of 2.84%. The stock has underperformed recently, losing 6.65% over the past week and trading below key moving averages, indicating a bearish trend despite increased investor participation.

As of 03-Dec, Max Healthcare Institute Ltd's stock price is falling, currently at 1,086.20, which reflects a decrease of 31.75 points or 2.84%. The stock has been underperforming, having lost 6.65% over the past week and 5.26% over the past month, contrasting with a slight gain of 1.34% in the Sensex during the same one-month period. <BR><BR>Today, the stock has experienced a consecutive decline for three days, resulting in a total drop of 6.61% during this timeframe. It reached an intraday low of Rs 1,077.95, indicating a significant downward movement of 3.58%. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, further suggesting a bearish trend.<BR><BR>Despite a rise in investor participation, with delivery volume increasing by 24.48% against the 5-day average, the overall performance today has underperformed the sector by 1.94%. The company's valuation is considered very expensive, with a high enterprise value to capital employed ratio and a PEG ratio of 2.2, indicating that the stock may be overvalued compared to its peers. <BR><BR>While the company has shown healthy long-term growth and consistent returns over the past three years, these factors are overshadowed by the current price decline and the stock's performance relative to the broader market.